Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Emilie Scherrer"'
Autor:
Raquel Aguiar-Ibáñez, Emilie Scherrer, Dmitri Grebennik, John Cook, Shalini Bagga, Baanie Sawhney, Anvi Khandelwal, Scott A. Soefje
Publikováno v:
BMC Health Services Research, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Introduction A new dosing schedule for the oncology immunotherapy pembrolizumab, every 6 weeks (Q6W), has been approved by the U.S. FDA, reducing the frequency of visits to infusion centers. We quantified the time spent by oncologists, nurse
Externí odkaz:
https://doaj.org/article/a95b3147d0cb47f7912515827ebe0e3e
Autor:
Xiang-Lin Tan, Amy Le, Emilie Scherrer, Huilin Tang, Nick Kiehl, Jiali Han, Ruixuan Jiang, Scott J. Diede, Irene M. Shui
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundMore than 60% of all stage IV melanoma patients develop brain metastases, while melanoma brain metastases (MBM) is historically difficult to treat with poor prognosis.ObjectivesTo summarize clinical outcomes and prognostic factors in MBM pa
Externí odkaz:
https://doaj.org/article/4829faf92aa94029b9b665b8fe8a7746
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundUrothelial carcinoma (UC) is a common malignancy with significant associated mortality. Recent clinical trials suggest an emerging role for HER2-targeted therapy. Testing for HER2 expression in UC is not part of current routine clinical pra
Externí odkaz:
https://doaj.org/article/209403f10bd94a99abbc0f28e2230f74
Autor:
Xiang-Lin Tan, Amy Le, Fred C. Lam, Emilie Scherrer, Robert G. Kerr, Anthony C. Lau, Jiali Han, Ruixuan Jiang, Scott J. Diede, Irene M. Shui
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundUp to 60% of melanoma patients develop melanoma brain metastases (MBM), which traditionally have a poor diagnosis. Current treatment strategies include immunotherapies (IO), targeted therapies (TT), and stereotactic radiosurgery (SRS), but
Externí odkaz:
https://doaj.org/article/3d136fcfb90e48cda5455a82cce40bd0
Autor:
Charles L. Cowey, Marley Boyd, Kathleen M. Aguilar, April Beeks, Clemens Krepler, Emilie Scherrer
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 7863-7878 (2020)
Abstract Introduction Anti‐PD‐1 monotherapies (aPD‐1) and BRAF/MEK inhibitors (BRAF/MEKi) changed the BRAF‐mutant advanced melanoma treatment landscape. This study aimed to improve the understanding of real‐world treatment patterns and opti
Externí odkaz:
https://doaj.org/article/ee976dd75d584d12914c8df2bc5510e8
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/1bfc61267f7a45059e87b4fee703575b
Autor:
Rachael Miller, Sophie Walker, Irene Shui, Agnes Brandtmüller, Kevin Cadwell, Emilie Scherrer
Publikováno v:
Melanoma Management, Vol 7, Iss 1 (2020)
Aim: Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II–III CM. Materials & methods: Systematic searche
Externí odkaz:
https://doaj.org/article/35e45945d96049ceb999513ef2ad683a
Autor:
Irene M, Shui, Emilie, Scherrer, Andrew, Frederickson, Joyce W, Li, Anel, Mynzhassarova, Eric, Druyts, Hussein, Tawbi
Publikováno v:
Melanoma Research. 32:393-404
Nearly half of advanced melanoma patients do not achieve a clinical response with anti-programmed cell death 1 protein (PD1) therapy (i.e. primary resistance) or initially achieve a clinical response but eventually progress during or following furthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24277db8ff02d4b150d4a28e6f90efe7
https://doi.org/10.1097/cmr.0000000000000850
https://doi.org/10.1097/cmr.0000000000000850
Autor:
Wen-Xi, Tang, Rong-Jie, Shao, Jingshu, Wang, Emilie, Scherrer, Ai-Xia, Ma, Raquel, Aguiar-Ibáñez
Publikováno v:
Value in Health Regional Issues. 27:99-107
This study aimed to evaluate the cost-effectiveness of pembrolizumab compared with standard-of-care chemotherapy (paclitaxel + carboplatin [PC]) in patients with unresectable or metastatic melanoma after first-line treatment from a Chinese healthcare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ae422b816fc14914ad74a0af85da7dc
https://doi.org/10.1016/j.vhri.2021.04.007
https://doi.org/10.1016/j.vhri.2021.04.007
Autor:
Xiang-Lin Tan, Amy Le, Huilin Tang, Madeline Brown, Emilie Scherrer, Jiali Han, Ruixuan Jiang, Scott J. Diede, Irene M. Shui
Publikováno v:
Cancers. 14(24)
Melanoma can frequently metastasize to the brain with severe consequences. However, variation of melanoma brain metastases (MBM) development among populations is not well studied, and underlying mechanisms and risk factors for MBM development are not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beb290ffe2438d1d74434f3522a37a1f
https://pubmed.ncbi.nlm.nih.gov/36551594
https://pubmed.ncbi.nlm.nih.gov/36551594